Icatibant Teva (Icatibant Acetate)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dose of Icatibant Teva is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. The product is supplied as a 30 mg/0.3 mL solution for subcutaneous injection, and the prescriber will specify the exact dosing regimen.

Safety of Icatibant in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Icatibant Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑esterase inhibitor concentrates replace the deficient protein. Icatibant offers a rapid, subcutaneous, on‑demand option that does not require intravenous administration, making it convenient for self‑treatment during acute attacks.

Icatibant Teva should be stored at 2–8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Icatibant Teva is administered as a subcutaneous injection. The 30 mg/0.3 mL solution is injected into the abdominal wall or thigh using a sterile needle, typically by the patient or a caregiver after proper training from a healthcare professional.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hypotension, and laryngeal edema that can compromise the airway. Patients should be monitored for these events, and immediate medical attention is required if they occur.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Patients taking ACE inhibitors or angiotensin receptor blockers should avoid concurrent use due to the increased risk of angioedema, unless specifically directed by a physician.